Effect of empagliflozin on Myocardial Infarction in Patients with Type 2 Diabetes and Cardiovascular Disease
Study Summary
This study investigated the impact of empagliflozin, a drug used to treat type 2 diabetes, on the risk of experiencing heart attacks in patients with both type 2 diabetes and cardiovascular disease. The study followed 7020 participants for an average of 3.1 years and found that empagliflozin reduced the risk of myocardial infarction (MI) events by 21% when compared to a placebo.
Practical Implications
Empagliflozin was found to be effective in reducing the risk of different types of heart attacks, particularly those related to plaque rupture/thrombus and myocardial supply-demand imbalance. This suggests that empagliflozin could be a valuable treatment option for patients with type 2 diabetes and cardiovascular disease to lower the risk of heart attacks.
Clinical trial details | PMID:38992713 | DOI:10.1186/s12933-024-02328-6
Integrating Research into Everyday Medical Practice
Clinical trials play a crucial role in developing safe and effective treatments. Our AI-driven platform, DocSym, integrates the latest clinical protocols and research into a user-friendly knowledge base for healthcare providers, making it easier to implement evidence-based treatments.
Streamlining Operations in Healthcare
Efficient management of patient care is essential in modern healthcare. Our mobile apps support scheduling, treatment monitoring, and telemedicine, enabling healthcare providers to streamline their services and improve patient outcomes.
AI technology can help clinics enhance their workflows and reduce paperwork, ultimately leading to better patient care. Discover more about our solutions at aidevmd.com.
